AbbVie Inc. is 195.0x more valuable than Immunome Inc. by market capitalization ($399.47 B vs $2.05 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMNM | ABBV |
|---|---|---|
| Market cap | $2.05 B | $399.47 B |
| US-listed rank | #2082 | #28 |
| Revenue (latest FY) | $6.94M | $61.16B |
| Net income (latest FY) | -$212.39M | $4.23B |
| Net margin | -3060.0% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 416 | 1,008 |
AbbVie Inc. is 195.0x more valuable than Immunome Inc. by market capitalization ($399.47 B vs $2.05 B).
In their latest fiscal years, Immunome Inc. reported $6.94M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Immunome Inc. and AbbVie Inc., or browse the full rankings.